NCT04883333View on ClinicalTrials.gov

A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

May 17, 2021

Primary Completion Date

July 18, 2022

Study Completion Date

July 18, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

LEO 153339

LEO 153339

DRUG

Placebo

Placebo

Trial Locations (1)

9728

LEO Pharma Investigational Site, Groningen

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

ICON plc

INDUSTRY

lead

LEO Pharma

INDUSTRY